{"id":"W4233437943","doi":"10.1016/j.annonc.2021.07.011","title":"Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’","year":2021,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Medicine; Oncology; Internal medicine; Cancer; Hormone receptor; Progression-free survival; Breast cancer; Metastatic breast cancer; Estrogen receptor; Epidermal growth factor receptor; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004105677,0.001899245,0.003337994,0.00263142,0.00168234,0.003743699,0.003168183,0.008584662,0.08310287],"category_scores_gemma":[0.03108148,0.0013509,0.002922231,0.001855265,0.001188244,0.001427736,0.001262935,0.01109601,0.04976745],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004398686,"about_ca_system_score_gemma":0.00493391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02346483,"about_ca_topic_score_gemma":0.04575351,"domain_scores_codex":[0.9967179,0.0006311729,0.0005145728,0.0004544586,0.001285594,0.0003962218],"domain_scores_gemma":[0.9865381,0.00467546,0.0009965065,0.0005684409,0.005938369,0.001283294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000424315,0.000005548434,0.00001643384,0.0000421797,0.00000793654,0.00002605609,0.000001603304,0.0000124495,0.000009394344,0.00005757896,0.9975661,0.002212369],"study_design_scores_gemma":[0.0004463359,0.00006578839,0.0009704917,0.0003465576,0.0001033163,0.0001549479,0.0000135441,0.000159829,0.0001099765,0.0005670183,0.997032,0.00003009775],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.00007057386,0.002605,0.0002005139,0.1024462,0.8869929,0.00006408394,0.001983439,0.0001953865,0.005441831],"genre_scores_gemma":[0.002986609,0.008789763,0.001343622,0.3144472,0.4854315,0.0003205037,0.00539227,0.0005625952,0.1807259],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.9914153,"threshold_uncertainty_score":0.2780068,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05281472117392018,"score_gpt":0.3807381026792624,"score_spread":0.3279233815053423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}